****DEPARTMENT OF HEALTH SERVICES STATE OF WISCONSIN**

Division of Medicaid Services Wis. Admin. Code § DHS 107.10(2)

F-01430 (12/2021)

**FORWARDHEALTH**

**PRIOR AUTHORIZATION DRUG ATTACHMENT FOR XYREM AND XYWAV**

**INSTRUCTIONS:** Type or print clearly. Before completing this form, read the Prior Authorization Drug Attachment for Xyrem and Xywav Instructions, F‑01430A. Providers may refer to the Forms page of the ForwardHealth Portal at <https://www.forwardhealth.wi.gov/WIPortal/Subsystem/Publications/ForwardHealthCommunications.aspx?panel=Forms> for the completion instructions.

Pharmacy providers are required to have a completed Prior Authorization Drug Attachment for Xyrem and Xywav form signed and dated by the prescriber before submitting a prior authorization (PA) request on the Portal, by fax, or by mail. Providers may call Provider Services at 800‑947‑9627 with questions.

|  |
| --- |
| **SECTION I – MEMBER INFORMATION** |
| 1. Name – Member (Last, First, Middle Initial)      |
| 2. Member ID Number      | 3. Date of Birth – Member      |
| **SECTION II – PRESCRIPTION INFORMATION**  |
| 4. Drug Name      | 5. Drug Strength       |
| 6. Date Prescription Written      | 7. Directions for Use      |
| 8. Refills      |
| 9. Name – Prescriber      | 10. National Provider Identifier – Prescriber      |
| 11. Address – Prescriber (Street, City, State, Zip+4 Code)      |
| 12. Phone Number – Prescriber      |
| **SECTION III A – CLINICAL INFORMATION**  |
| **Note:** A copy of the member’s current medical records that support a clinical correlation between the member’s test results and the member’s medical condition of narcolepsy with cataplexy, narcolepsy without cataplexy, or idiopathic hypersomnia must be submitted with the PA request, including the following:* Test results and provider interpretation for the polysomnogram and Multiple Sleep Latency Test (MSLT)
* For members with excessive daytime sleepiness (EDS), a copy of the Epworth Sleepiness Scale (ESS) questionnaire, Maintenance of Wakefulness Test (MWT), or MSLT
* For renewal PA requests, medical record documentation demonstrating clinical improvement, including a decrease in cataplexy or a decrease in the member’s daytime sleepiness, supported by an ESS questionnaire, MWT, or MSLT
 |
| 13. Diagnosis Code and Description      |
| 14. Does the member have narcolepsy with cataplexy? [ ]  Yes [ ]  NoIf yes, indicate in the space below the cataplexy symptoms experienced by the member and how frequently they occur.      |
| 15. Does the member have narcolepsy without cataplexy? [ ]  Yes [ ]  No |
| 16. Does the member have idiopathic hypersomnia? [ ]  Yes [ ]  No |
| 17. Does the member have a succinic semialdehyde dehydrogenase deficiency? [ ]  Yes [ ]  No |
| 18. As required by the Xywav and Xyrem Risk Evaluation and Mitigation Strategy (REMS) Program: * Has the prescriber counseled the member on the contraindication between Xyrem or Xywav and alcohol? [ ]  Yes [ ]  No
* Has the member agreed to be abstinent from alcohol while being treated with Xyrem or Xywav? [ ]  Yes [ ]  No
 |
| 19. Indicate which symptom(s) of narcolepsy or idiopathic hypersomnia Xyrem or Xywav is being used to treat.[ ]  Cataplexy[ ]  Excessive Daytime Sleepiness[ ]  Other       |
| 20. Does the member have a history of substance abuse, addiction, or diversion? [ ]  Yes [ ]  No |
| 21. Is the member taking any sedative hypnotics? [ ]  Yes [ ]  No |
| 22. Is the member taking central nervous system (CNS) depressants (for example, anxiolytics, barbiturates, or opioids)? [ ]  Yes [ ]  No If yes, indicate the CNS depressants and daily doses.1.      2.      3.      Are any of the above listed CNS depressants contributing to the member’s daytime sleepiness? [ ] Yes [ ]  NoIf no, indicate how the prescriber evaluated the CNS depressants and determined they are not contributing to the member’s daytime sleepiness.       |
| 23. Has the member had an overnight polysomnogram sleep study followed by an MSLT? [ ]  Yes [ ]  No |
| 24. Does the member have EDS that interferes with normal activities on a daily basis? [ ]  Yes [ ]  No |
| 25. Has the member completed an ESS questionnaire, MWT, or MSLT? [ ]  Yes [ ]  No |
| 26. Has the prescriber ruled out or treated the member for each of the following potential causes of EDS? [ ]  Yes [ ]  No* Other sleep disorders including sleep apnea
* Chronic pain or illness that disrupts normal sleep patterns
* Mood disorders such as depression
* Caffeine or nicotine use causing poor quality of nighttime sleep
 |
| 27. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction with a stimulant? [ ]  Yes [ ]  NoIf yes, list the stimulant and dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates the stimulant was taken in the space provided.      |
| 28. Does the member have a medical condition(s) preventing the use of a stimulant? [ ]  Yes [ ]  NoIf yes, list the medical condition(s) that prevents the use of a stimulant in the space provided.      |
| 29. Is there a clinically significant drug interaction(s) between another medication(s) the member is taking and stimulants? [ ]  Yes [ ]  NoIf yes, list the medication(s) and drug interaction(s) in the space provided.      |
| 30. Has the member experienced an unsatisfactory therapeutic response after the medication has been titrated to a maximum recommended daily dose or experienced a clinically significant adverse drug reaction with armodafinil or modafinil? [ ]  Yes [ ]  NoIf yes, list the drug and dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates armodafinil or modafinil were taken in the space provided.      |
| 31. Does the member have a medical condition(s) preventing the use of armodafinil or modafinil? [ ]  Yes [ ]  NoIf yes, list the medical condition(s) that prevents the use of armodafinil or modafinil in the space provided.      |
| 32. Is there a clinically significant drug interaction(s) between another medication(s) the member is taking and armodafinil or modafinil? [ ]  Yes [ ]  NoIf yes, list the medication(s) and drug interaction(s) in the space provided.      |
| 33. Has the member experienced an unsatisfactory therapeutic response or experienced a clinically significant adverse drug reaction with tricyclic antidepressant (TCA), selective serotonin reuptake inhibitor (SSRI), or serotonin norepinephrine reuptake inhibitor (SNRI)? [ ]  Yes [ ]  NoIf yes, list the TCA, SSRI, or SNRI and dose, specific details about the unsatisfactory therapeutic response or clinically significant adverse drug reaction, and the approximate dates the TCA, SSRI, or SNRI was taken in the space provided.       |
| **SECTION III B – ADDITIONAL CLINICAL INFORMATION FOR XYWAV PA REQUESTS FOR NARCOLEPSY ONLY** |
| 34. PA requests for Xywav must include detailed clinical justification for prescribing Xywav instead of Xyrem. This clinical information must document why the member cannot use Xyrem, including why it is medically necessary that the member receive Xywav instead of Xyrem.      |
| **SECTION IV – AUTHORIZED SIGNATURE** |
| 35. **SIGNATURE** –Prescriber | 36. Date Signed |
| **SECTION V – ADDITIONAL INFORMATION** |
| 37. Include any additional information in the space below. Additional diagnostic and clinical information explaining the need for the drug requested may also be included here.      |